Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation je kožný stav charakterizovaný zvýšeným pigmentom v koži po zápale kože. Postinflammatory hyperpigmentation môže byť spôsobená dlhodobým pobytom na slnku, zápalom alebo inými poraneniami kože, vrátane tých, ktoré súvisia s akné. Ľudia s tmavším odtieňom pleti sú zvyčajne náchylnejší na hyperpigmentáciu pri nadmernom slnení.
☆ Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
References
Postinflammatory hyperpigmentation (PIH) je častý kožný problém, ktorý sa vyskytuje po zápale alebo poranení kože. Má tendenciu trvať dlho a je horšia u ľudí s tmavším odtieňom pleti (Fitzpatrick skin types III–VI) . Aj keď sa to často zlepší samo, môže to chvíľu trvať, takže liečba je často potrebná na dlhú dobu. Najlepšie funguje kombinácia rôznych liečebných postupov.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation je bežným následkom zápalu kože. Závažnejšie a častejšie postihuje jedincov tmavšej pleti. Štúdie ukazujú, že problémy ako postinflammatory hyperpigmentation patria medzi hlavné dôvody, prečo ľudia s tmavším odtieňom pleti vyhľadávajú dermatologickú starostlivosť. Včasná liečba je rozhodujúca pre vyriešenie postinflammatory hyperpigmentation a zvyčajne začína zvládnutím počiatočného zápalového stavu. Prvá línia liečby zvyčajne zahŕňa použitie lokálnych činidiel, ktoré zosvetľujú pokožku spolu s opaľovacím krémom na ochranu. Tieto činidlá, ako hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , môžu účinne znížiť nadmernú pigmentáciu. Okrem toho sa retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy používajú aj ako depigmentačné činidlá, pričom sa objavujú nové spôsoby liečby. Zatiaľ čo lokálne liečby sú zvyčajne účinné pri povrchovej hyperpigmentácii, v tvrdohlavých prípadoch môžu byť potrebné postupy (laser, chemical peel) . Je dôležité pri týchto liečebných postupoch postupovať opatrne, aby ste sa vyhli podráždeniu a zhoršeniu postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
